177Lu-IM-3050

N/A

Report date: 2026/04/03 20:03:44

Base Information

Drug Name177Lu-IM-3050
Drug Alias Name177Lu-IM-3050
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177Lu
Mechanisms of ActionFibroblast activation protein alpha modulatorsPositron-emission tomography enhancers
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesSecond Affiliated Hospital School Of Zhejiang University School Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesImmunome Inc
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A